Mark D. McKee
Impact in
- Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- PARP inhibition in cancer therapy
Papers in
- Oncology 33
- PARP inhibition in cancer therapy 17
- CAR-T cell therapy research 7
- Cancer Treatment and Pharmacology 5
-
- DNA Repair Mechanisms 5
- Co-authors
- Thomas F. Gajewski (2 shared papers)Yuanyuan Zha (1 shared paper)Maria Tretiakova (1 shared paper)Helena Harlin (2 shared papers)Amy Peterson (1 shared paper)Craig L. Slingluff (1 shared paper)Yuru Meng (1 shared paper)Danielle Sullivan (6 shared papers)
- Journals
- Journal of Clinical Oncology (15 papers)Journal of Immunotherapy (5 papers)Annals of Oncology (4 papers)Blood (2 papers)The Journal of Immunology (2 papers)
- Partner nations
- United StatesRussiaGermany
In The Last Decade
Mark D. McKee
44 papers receiving 2.6k citations
Mark D. McKee's Hit Papers
Peers
Comparison fields: 5 of 91
- Hepatology 419
- Oncology 1.4k
- Immunology 846
- Cancer Research 407
- Pathology and Forensic Medicine 263
Countries citing papers authored by Mark D. McKee
This map shows the geographic impact of Mark D. McKee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark D. McKee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark D. McKee more than expected).
Fields of papers citing papers by Mark D. McKee
This network shows the impact of papers produced by Mark D. McKee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark D. McKee. The network helps show where Mark D. McKee may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark D. McKee, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 46 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment Hit paper breakdown → | 2009 | 879 |
| 2 | Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial Hit paper breakdown → | 2018 | 537 |
| 3 | Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial Hit paper breakdown → | 2014 | 470 |
| 4 | 1999 | 89 | |
| 5 | 2015 | 72 | |
| 6 | 2013 | 63 | |
| 7 | 2018 | 59 | |
| 8 | 2009 | 58 | |
| 9 | 2017 | 47 | |
| 10 | 2003 | 46 | |
| 11 | 2006 | 32 | |
| 12 | 2005 | 27 | |
| 13 | 2009 | 26 | |
| 14 | 2018 | 24 | |
| 15 | 2015 | 20 | |
| 16 | 2012 | 19 | |
| 17 | 2018 | 18 | |
| 18 | 2014 | 17 | |
| 19 | 2018 | 14 | |
| 20 | 2013 | 13 |
About Mark D. McKee
Mark D. McKee is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Immunology and Cell Biology, having authored 46 papers that have together received 2.6k indexed citations. Recurring topics across this work include PARP inhibition in cancer therapy (17 papers), CAR-T cell therapy research (7 papers), Immunotherapy and Immune Responses (7 papers), T-cell and B-cell Immunology (6 papers), Lung Cancer Treatments and Mutations (6 papers), DNA Repair Mechanisms (5 papers), Cancer Treatment and Pharmacology (5 papers) and Immune Cell Function and Interaction (5 papers). The work is most often cited by research in Hepatology (419 citations), Oncology (1.4k citations), Immunology (846 citations), Cancer Research (407 citations) and Pathology and Forensic Medicine (263 citations). Mark D. McKee has collaborated with scholars based in United States, Russia and Germany. Frequent co-authors include Thomas F. Gajewski, Yuanyuan Zha, Maria Tretiakova, Helena Harlin, Amy Peterson, Craig L. Slingluff, Yuru Meng, Danielle Sullivan, Michael I. Nishimura and Jiang Qian. Their work appears in journals such as Journal of Clinical Oncology, Journal of Immunotherapy, Annals of Oncology, Blood and The Journal of Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.